Aktieanalys

Alzecure: Selects ACD137 as a drug candidate within TrkA-NAM project - Redeye

Redeye Publicerad: 29 Jan 13:19

Redeye has a positive take on today’s news that Alzecure has advanced ACD137 as a drug candidate as part of its TrkA-NAM project and will now move into preclinical development. While early stage, the target is well established in our view and could generate early interest from potential partners. Recently, the Japanese company Asahi Kasei also advanced its TrkA-NAM project into phase IIb targeting osteoarthritic pain, indicating current activity relating to the target. We will return with a more thorough view in relation to our Q4 update.

Länk till analysen i sin helhet: https://www.redeye.se/research/972876/alzecure-selects-acd137-as-a-drug-candidate-within-trka-nam-project?utm_source=finwire&utm_medium=RSS

Nyheter om AlzeCure Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!